Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial. // The Lancet Child & Adolescent Health. – URL: https://www.sciencedirect.com/science/article/pii/S2352464226001641?dgcid=rss_sd_all
Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial. The Lancet Child & Adolescent Health. https://www.sciencedirect.com/science/article/pii/S2352464226001641?dgcid=rss_sd_all
“Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial.” The Lancet Child & Adolescent Health.
@article{article101657,
title = {Immunogenicity up to age 5 years following a single-dose or two-dose infant primary series of 10-valent or 13-valent pneumococcal conjugate vaccine each followed by a booster dose in South Africa: extended follow-up of a single-centre, open-label, non-inferiority, randomised controlled trial},
journal = {The Lancet Child \& Adolescent Health},
url = {https://www.sciencedirect.com/science/article/pii/S2352464226001641?dgcid=rss_sd_all}
}